Neximmune

Neximmune Inventory

The Inventory of Neximmune (NEXI) as of Nov 18, 2026 is -19,467.00 USD. In the previous year, Inventory was 61,079.00 USD — a change of -131.87% (lower).

Inventory

-19,467.00USD

YoY

-131.87%

Last updated:

Inventory of Neximmune is 2022 -19,467.00 USD. Inventory of Neximmune was 2021 61,079.00 USD. It decreases by -131.87% lower compared to the previous year.

The Neximmune Inventory history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory
Date
Inventory
Jan 1, 2019
61,079.00 USD
Jan 1, 2022
-19,467.00 USD
The Neximmune Inventory history
YEARInventoryYoY
-19,467.00USD-131.87%
61,079.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neximmune Stock analysis

What does Neximmune do? Neximmune Inc develops immunotherapy approaches using its AIM technology, a nanoparticle platform that mimics natural biology to direct T cell responses. The company's product candidates include NEXI-001 for acute myeloid leukemia (AML) and NEXI-002 for multiple myeloma (MM), both designed to combine cellular therapy attributes with reduced toxicity. Neximmune focuses on clinical-stage development for oncology and autoimmune disorders, leveraging its AIM nanoparticles to deliver specific immune responses through signaling proteins. The company targets pharmaceutical and biotechnology sectors with its T cell-based therapies, aiming to address unmet medical needs in cancer treatment. Its AIM technology platform enables the creation of synthetic dendritic cells that instruct T cells to generate targeted immune responses, differentiating its approach from conventional immunotherapies. Neximmune's clinical pipeline includes multiple product candidates in various stages of development for oncology applications. Neximmune's revenue model is based on the development and potential future commercialization of its immunotherapy products. The company is currently in clinical development, with no commercialized products yet, focusing on advancing NEXI-001 and NEXI-002 through clinical trials to demonstrate efficacy and safety for regulatory approval. Neximmune is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neximmune stock

Inventory of Neximmune is -19,467.00 USD in 2022.

Inventory of Neximmune changed from 61,079.00 USD to -19,467.00 USD, representing a -131.87% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Inventory Neximmune since 2006 – with annual values, charts, and detailed analysis.

Inventory includes raw materials, work-in-progress, and finished goods. Efficient inventory management is crucial for profitability.

Inventory's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Inventory's Neximmune historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Neximmune

All Key Metrics — Neximmune